

Citations

- Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., Zhang, J., Piulats, J. M., Ryan, C. J., Merseburger, A. S., Daugaard, G., Heidenreich, A., Fizazi, K., Higano, C. S., Krieger, L. E., Sternberg, C. N., ... TRITON2 investigators (2020). Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a *BRCA1* or *BRCA2* Gene Alteration. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 38(32), 3763–3772. <https://doi.org/10.1200/JCO.20.01035>
- Antonarakis, E. S., Isaacsson Velho, P., Fu, W., Wang, H., Agarwal, N., Sacristan Santos, V., Maughan, B. L., Pili, R., Adra, N., Sternberg, C. N., Vlachostergios, P. J., Tagawa, S. T., Bryce, A. H., McNatty, A. L., Reichert, Z. R., Dreicer, R., Sartor, O., Lotan, T. L., & Hussain, M. (2020). *CDK12*-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. *JCO precision oncology*, 4, 370–381. <https://doi.org/10.1200/po.19.00399>
- Cheng, H. H., Pritchard, C. C., Montgomery, B., Lin, D. W., & Nelson, P. S. (2017). Prostate Cancer Screening in a New Era of Genetics. *Clinical genitourinary cancer*, 15(6), 625–628. <https://doi.org/10.1016/j.clgc.2017.05.024>
- Clarke, N., Wiechno, P., Alekseev, B., Sala, N., Jones, R., Kocak, I., Chiuri, V. E., Jassem, J., Fléchon, A., Redfern, C., Goessl, C., Burgents, J., Kozarski, R., Hodgson, D., Learoyd, M., & Saad, F. (2018). Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet. Oncology*, 19(7), 975–986. [https://doi.org/10.1016/S1470-2045\(18\)30365-6](https://doi.org/10.1016/S1470-2045(18)30365-6)
- Corn, P. G., Heath, E. I., Zurita, A., Ramesh, N., Xiao, L., Sei, E., Li-Ning-Tapia, E., Tu, S.-M., Subudhi, S. K., Wang, J., Wang, X., Efstathiou, E., Thompson, T. C., Troncoso, P., Navin, N., Logothetis, C. J., & Aparicio, A. M. (2019). Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. In *The Lancet Oncology* (Vol. 20, Issue 10, pp. 1432–1443). Elsevier BV. [https://doi.org/10.1016/s1470-2045\(19\)30408-5](https://doi.org/10.1016/s1470-2045(19)30408-5)
- de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., Thiery-Vuillemin, A., Twardowski, P., Mehra, N., Goessl, C., Kang, J., Burgents, J., Wu, W., Kohlmann, A., Adelman, C. A., & Hussain, M. (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. *The New England journal of medicine*, 382(22), 2091–2102. <https://doi.org/10.1056/NEJMoa1911440>
- Giri, V. N., Knudsen, K. E., Kelly, W. K., Abida, W., Andriole, G. L., Bangma, C. H., Bekelman, J. E., Benson, M. C., Blanco, A., Burnett, A., Catalona, W. J., Cooney, K. A., Cooperberg, M., Crawford, D. E., Den, R. B., Dicker, A. P., Eggen, S., Fleshner, N., Freedman, M. L., Hamdy, F. C., ... Gomella, L. G. (2018). Role of Genetic Testing for

Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 36(4), 414–424. <https://doi.org/10.1200/JCO.2017.74.1173>

Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N. D., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., Thiery-Vuillemin, A., Twardowski, P., Mehra, N., Goessl, C., Kang, J., Burgents, J., Wu, W., Kohlmann, A., Adelman, C. A., & de Bono, J. (2019). PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. In *Annals of Oncology* (Vol. 30, pp. v881–v882). Elsevier BV. <https://doi.org/10.1093/annonc/mdz394.039>

Moreno, J. G., & Gomella, L. G. (2019). Evolution of the Liquid Biopsy in Metastatic Prostate Cancer. In *Urology* (Vol. 132, pp. 1–9). Elsevier BV. <https://doi.org/10.1016/j.urology.2019.06.006>

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., Elemento, O., Rubin, M. A., Robinson, D., Lonigro, R., Hussain, M., Chinnaiyan, A., Vinson, J., Filipenko, J., Garraway, L., Taplin, M. E., ... Nelson, P. S. (2016). Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *The New England journal of medicine*, 375(5), 443–453. <https://doi.org/10.1056/NEJMoa1603144>